# Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, to Healthy Male and Female Volunteers, With an Intra-individual Comparison to Moxifloxacin in a Subset of Volunteers

> **NCT02264015** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 125 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Cilobradine, low, film-coated tablets
- **DRUG:** Cilobradine, high, film-coated tablets
- **DRUG:** Placebo, film-coated tablets
- **DRUG:** Moxifloxacin, film-coated tablets

## Key facts

- **NCT ID:** NCT02264015
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2004-05
- **Final completion:** —
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2014-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02264015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02264015, "Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, to Healthy Male and Female Volunteers, With an Intra-individual Comparison to Moxifloxacin in a Subset of Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02264015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*